Advanced search
Publication Cover
Pediatric Hematology and Oncology Volume 20, 2003 - Issue 3
Submit an article Journal homepage
10
Views
0
CrossRef citations to date
0
Altmetric
Research Article

New Antileukemic Agents

Elpis Mantadakis Pediatric Hematology/Oncology Clinic, University Hospital of Heraklion, Heraklion, Crete, Greece
&
Maria Kalmanti Pediatric Hematology/Oncology Clinic, University Hospital of Heraklion, Heraklion, Crete, Greece
Pages 173-185 | Published online: 09 Jul 2009

  • Giles FJ. Novel agents for the therapy of acute leukemia. Curr Opin Oncol. 2002;14:3-9.
  • Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med. 1998;339:605-615.
  • Traxler P, Bold G, Buchdunger E, et al. Tyrosine kinase inhibitors: from rational design to clinical trials. Med Res Rev. 2001;21:499-512.
  • Savage DG, Antman KH. Imatinib mesylate: a new oral targeted therapy. N Engl J Med. 2002;346:683-693.
  • Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Gin Invest. 2000;105:3-7.
  • Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the bcr-abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
  • Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the bcr-abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038-1042.
  • Druker B. Signal transduction inhibition: results from phase I clinical trials in chronic myeloid leukemia. Semin Hematol. 2001;38(3 Suppl 8):9-14.
  • Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologie and cytogenetic responses in patients with accelerated phase chronic myelogenous leukemia: results of a phase 2 study. Blood. 2002;99:1928-1937.
  • Talpaz M, Silver RT, Druker B, et al. Gleevec[(tm)]: an active drug in patients with Ph+ chronic myeloid leukemia in accelerated phase: updated results of a phase II study. Proc Am Soc Hematol. 2001 ; abstract 3509.
  • Sawyers CL, Hochhaus A, Feldman E, etal. Gleevec/Glivec (imatinib mesylate, STI-571) in patients with chronic myeloid leukemia in myeloid blast crisis: updated results of a phase II study. Proc Am Soc Hematol. 2001; abstract 3510.
  • Scappini B, Onida F, Kantarjian HM, et al. In vitro effects of STl 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells. Cancer. 2002;94:2653-2662.
  • Hoover RR, Mahon FX, MeIo JV, Daley GQ. Overcoming STI571 resistance with the famesyl transferase inhibitor SCH66336. Blood. 2002; 100:1068-1071.
  • O'Brien S, Talpaz M, Cortes J, et al. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia. Cancer. 2002;94:2024-2032.
  • le Coutre P, Tassi E, Varella-Garcia M, et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood. 2000;95:1758-1766.
  • Weisberg E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cells. Blood. 2000;95:S498-3505.
  • Mahon FX, Deininger MW, Schultheis B, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanism of resistance. Blood. 2000;96:1070-1079.
  • Gambacorti-Passerini C, Barni R, Ie Coutre P, et al. Role of alphal acid glycoprotein in the in vivo resistance of human BCR-ABL(1) leukemic cells to the abl inhibitor 811571. J Natl Cancer Inst. 2000;92:1641-1650.
  • Barthe C, Gharbi MJ, Lagarde V, et al. Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukemia with increasing resistance to STI571. Br J Haematol. 2002;119:109-111.
  • Roumiantsev S, Shah NP, Gorre ME, et al. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the AbI kinase domain P-loop. Proc Natl Acad Set USA. 2002;99:10700-10705.
  • Hofmann WK, Jones LC, Lemp NA, et al. Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood. 2002;99:1860-1862.
  • Branford S, Rudzki Z, Walsh S, et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood. 2002;99:3472-3475.
  • Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, et al. Several types of mutations of the AbI gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment Blood. 2002;100:1014-1018.
  • Donate NJ, Ji Wu JY, Alitar M, et al. Multiple resistance mechanisms identified through studies of cell lines derived from chronic myelogenous leukemia patients progressing on IMATINIB/STI571 therapy. Proc Am Soc Hematol. 2001; abstract 3206.
  • Champagne MA, Hershon L, Rosamilia M, et al. STI571 in the treatment of pediatrie Philadelphia (Ph+) chromosome-positive leukemia: a Children's Oncology Group phase 1 study (P-9973). Proc Am Soc Clin Oncol. 2001; abstract 1466.
  • Stirewalt DL, Kopecky KJ, Meshinchi S, et al. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood. 2001;97:3589-3595.
  • Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML10 and 12 trials. Blood. 2001;98:1752-1759.
  • Rombouts WJ, Blokland I, Lowenberg B, et al. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. Leukemia. 2000; 14:675-683.
  • Kiyoi H, Towatari M, Yokota S, et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product Leukemia. 1998; 12:1333-1337.
  • Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologie malignancies. Blood. 2001;97:2434-2439.
  • Levis M, Tse KF, Smith BD, et al. A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. Blood. 2001 ;98:885-887.
  • Levis M, Abllebach J, Tse KF, et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood. 2002;99:3885-3891.
  • Weisberg E, Boulton C, Louise K, et al. Inhibition of mutant FLT3 receptors in leukemia cells by a small molecule tyrosine kinase inhibitor. Proc Am Soc Clin Oncol. 2002; abstract 16.
  • Karp JE, Lancet JE, Kaufmann SH, et al. Clinical and biologic activity of the famesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase I clinical laboratory correlative trial. Blood. 2001;97:3361-3369.
  • Kurzrock R, Cortes J, Ryback ME, et al. Phase II study of R115777, a famesyltransferase inhibitor, in myelodysplastic syndrome. Proc Am Soc Hematol. 2001 ; abstract 3520.
  • Mansour TS, Jin H, Wang W, et al. Anti-human immunodeficiency virus and anti-hepatitis-B virus activities and toxicities of the enantiomers of 2'-deoxy-3'-oxa-4'-thiocytidine and their 5-fluoro analogues in vitro. J. Med Chem. 1995;38:l-4.
  • Grove KL, Guo X, Liu SH, et al. Anticancer activity of beta-L-dioxolane-cytidine, a novel nucleoside analogue with the unnatural L configuration. Cancer Res. 1995;55:3008-3011.
  • Grove KL, Cheng YC. Uptake and metabolism of the new anticancer compound beta-L-(-)-dioxolanecytidine in human prostate carcinoma DU-145 cells. Cancer Res. 1996;56:4187-4191.
  • Kadhim SA, Bowlin TL, Waud WR, et al. Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (beta-L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models. Cancer Res. 1997;57:4803-4810.
  • Siu LL, Attardo G, Izbicka E, et al. Activity of (-)-2'-deoxy-3'-oxacytidine (BCH-4556) against human tumor colony-forming units. Ann OncoL 1998;9:885-891.
  • Giles FJ, Cortes JE, Baker SD, et al. Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia. J Clin Oncol. 2001;19:762-771.
  • Lambe CU, Averett DR, Faff MT, et al. 2-Amino-6-methoxypurine arabinoside: an agent for T-cell malignancies. Cancer Res. 1995;55:3352-3356.
  • Ullman B, Martin DW. Specific cytotoxicity of arabinosyl-guanine toward cultured T-lymphoblasts. J Clin lnvest. 1984;74:951-955.
  • Verhof V, Fridland A. Metabolic basis of arabinonucleoside selectivity for human leukemic T- and B-lymphoblasts. Cancer Res. 1985;45:3646-3650.
  • Kisor DF, Plunkett W, Kurtzberg J, etal. Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatrie and adult patients during a phase I study of nelarabine for the treatment of refractory hematologie malignancies. J Clin Oncol. 2000;18:995-1003.
  • Gandhi V, Plunkett W, Weller S, et al. Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells. J Clin Oncol. 2001;19:2142-2152.
  • Herman JG, Jen J, Merlo A, et al. Hypermethylation-associated inactivation indicates a suppressor role for p15INK4B1. Cancer Res. 1996;56:722-727.
  • Jones PA, Taylor SM. Cellular differentiation, cytidine analogues and DNA methylation. CeIl. 1980;20: 85-93.
  • Wijermans P, Lubbert M, Verhoef G, et al. Low-dose 5-aza-2/-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol. 2000;18:956-962.
  • Quesnel B, Fenaux P. P15INK4b gene methylation and myelodysplastic syndromes. Leak Lymphoma. 1999;35:437-443.
  • Uchida T, Kinoshita T, Hotta T, et al. High-risk myelodysplastic syndromes and hypermethylation of the p15Ink4B gene. Leak Lymphoma. 1998;32:9-18.
  • Ribatti D, Vacca A, De Falco G, et al. Angiogenesis, angiogenic factor expression and hematological malignancies. Anticancer Res. 2001;21:4333-4339.
  • Moehler TM, Neben K, Ho AD, et al. Angiogenesis in hematologie malignancies. Ann Hematol. 2001;80:695-705.
  • Keyhani A, Jendiroba DB, Freireich EJ. Angiogenesis and leukemia. Leak Res. 2001;25:639-645.
  • Aguayo A, O'Brien S, Keating M, et al. Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia. Blood. 2000;96:768-770.
  • Aguayo A, Kantarjian H, Manshouri T, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 2000;96:2240-2245.
  • Smolich BD, Yuen HA, West HA, et al. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood. 2001:97:1413-1421.
  • Mendel DB, Schreck RE, West DC, et al. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function. Clin Cancer Res. 2000;6:4848-4858.
  • Fong TA, Shawver LK, Sun L, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 1999;59:99-106.
  • Mesters RM, Padro T, Bieker R, et al. Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia. Blood 2001;98:241-243.
  • Fiedler W, Tinnefeid H, Mende T, et al. A phase II study with SU5416 in patients with C-Kit positive AML. Proc Am Soc Clin Oncol. 2001 ; abstract 1148.
  • Flynn JM, Byrd JC. Campath-lH monoclonal antibody therapy. Curr Opin Oncol. 2000;! 2:574-581.
  • Osterborg A, Dyer MJ, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-IH Treatment in Chronic Lymphocytic Leukemia. J. Clin Oncol. 1997;15:1567-1574.
  • Kennedy B, Rawstron A, Carter C, et al. Campath-lH and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood. 2002;99:2245-2247.
  • Rearing MJ, Cazin B, Coutre S, et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J. Clin Oncol. 2002;20:205-213.
  • Dearden CE, Matutes E, Cazin B, et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-IH. Stood. 2001;98:1721-1726.
  • Sievers EL, Appelbaum FR, Spielberger RT, et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood. 1999;93:3678-3684.
  • Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001;7:1490-1496.
  • Sievers EL, Larson RA, Stadtmauer EA, et al., for the Mylotarg Study Group. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J. Clin Oncol. 2001;19:3244-3254.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.